论文部分内容阅读
目的探讨沙美特罗/氟替卡松与噻托溴铵联合治疗D组稳定期慢性阻塞性肺疾病(COPD)患者的效果。方法将90例D组稳定期COPD患者分为三组:A组(沙美特罗/氟替卡松+噻托溴铵)、B组(沙美特罗/氟替卡松)和C组(噻托溴铵),每组各30例。对三组患者治疗前和治疗3个月后的呼吸困难评分、肺功能指标进行比较。结果治疗3个月后,A组患者呼吸困难评分及肺功能改善均优于B、C两组,差异有统计学意义(P<0.05)。结论联合使用沙美特罗/氟替卡松和噻托溴铵比单用沙美特罗/氟替卡松或单用噻托溴铵可以更好地改善D组稳定期COPD患者的呼吸困难评分和肺功能。
Objective To investigate the effect of salmeterol / fluticasone in combination with tiotropium on patients with stable chronic obstructive pulmonary disease (COPD) in group D. Methods Ninety patients with stable COPD in group D were divided into three groups: group A (salmeterol / fluticasone + tiotropium bromide), group B (salmeterol / fluticasone) and group C (tiotropium bromide) Group of 30 cases. Three groups of patients before treatment and 3 months after treatment of dyspnea score, lung function indicators were compared. Results After 3 months of treatment, the scores of dyspnea and the improvement of lung function in group A were better than those in group B and C (P <0.05). CONCLUSIONS: Salmeterol / fluticasone and tiotropium combined with salmeterol / fluticasone alone or tiotropium alone were associated with better dyspnea scores and lung function in patients with stable COPD in the D group.